313 related articles for article (PubMed ID: 11015437)
1. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response.
Do RK; Hatada E; Lee H; Tourigny MR; Hilbert D; Chen-Kiang S
J Exp Med; 2000 Oct; 192(7):953-64. PubMed ID: 11015437
[TBL] [Abstract][Full Text] [Related]
2. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells.
Hatada EN; Do RK; Orlofsky A; Liou HC; Prystowsky M; MacLennan IC; Caamano J; Chen-Kiang S
J Immunol; 2003 Jul; 171(2):761-8. PubMed ID: 12847243
[TBL] [Abstract][Full Text] [Related]
3. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers.
Rahman ZS; Manser T
J Immunol; 2004 Nov; 173(10):6179-88. PubMed ID: 15528355
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
5. APRIL modulates B and T cell immunity.
Stein JV; López-Fraga M; Elustondo FA; Carvalho-Pinto CE; Rodríguez D; Gómez-Caro R; De Jong J; Martínez-A C; Medema JP; Hahne M
J Clin Invest; 2002 Jun; 109(12):1587-98. PubMed ID: 12070306
[TBL] [Abstract][Full Text] [Related]
6. CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis.
Mineva ND; Rothstein TL; Meyers JA; Lerner A; Sonenshein GE
J Biol Chem; 2007 Jun; 282(24):17475-85. PubMed ID: 17446175
[TBL] [Abstract][Full Text] [Related]
7. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.
Ursini-Siegel J; Zhang W; Altmeyer A; Hatada EN; Do RK; Yagita H; Chen-Kiang S
J Immunol; 2002 Nov; 169(10):5505-13. PubMed ID: 12421926
[TBL] [Abstract][Full Text] [Related]
8. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity.
Yan M; Marsters SA; Grewal IS; Wang H; Ashkenazi A; Dixit VM
Nat Immunol; 2000 Jul; 1(1):37-41. PubMed ID: 10881172
[TBL] [Abstract][Full Text] [Related]
9. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases.
Nardelli B; Moore PA; Li Y; Hilbert DM
Leuk Lymphoma; 2002 Jul; 43(7):1367-73. PubMed ID: 12389615
[TBL] [Abstract][Full Text] [Related]
10. An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.
Anderson JS; Teutsch M; Dong Z; Wortis HH
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10966-71. PubMed ID: 8855292
[TBL] [Abstract][Full Text] [Related]
11. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.
Moore PA; Belvedere O; Orr A; Pieri K; LaFleur DW; Feng P; Soppet D; Charters M; Gentz R; Parmelee D; Li Y; Galperina O; Giri J; Roschke V; Nardelli B; Carrell J; Sosnovtseva S; Greenfield W; Ruben SM; Olsen HS; Fikes J; Hilbert DM
Science; 1999 Jul; 285(5425):260-3. PubMed ID: 10398604
[TBL] [Abstract][Full Text] [Related]
12. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF.
Tardivel A; Tinel A; Lens S; Steiner QG; Sauberli E; Wilson A; Mackay F; Rolink AG; Beermann F; Tschopp J; Schneider P
Eur J Immunol; 2004 Feb; 34(2):509-18. PubMed ID: 14768056
[TBL] [Abstract][Full Text] [Related]
13. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways.
Zarnegar B; He JQ; Oganesyan G; Hoffmann A; Baltimore D; Cheng G
Proc Natl Acad Sci U S A; 2004 May; 101(21):8108-13. PubMed ID: 15148378
[TBL] [Abstract][Full Text] [Related]
14. Dominant signals leading to inhibitor kappaB protein degradation mediate CD40 ligand rescue of WEHI 231 immature B cells from receptor-mediated apoptosis.
Schauer SL; Bellas RE; Sonenshein GE
J Immunol; 1998 May; 160(9):4398-405. PubMed ID: 9574544
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis.
Zhang X; Li L; Choe J; Krajewski S; Reed JC; Thompson C; Choi YS
Cell Immunol; 1996 Oct; 173(1):149-54. PubMed ID: 8871610
[TBL] [Abstract][Full Text] [Related]
16. Activation and accumulation of B cells in TACI-deficient mice.
Yan M; Wang H; Chan B; Roose-Girma M; Erickson S; Baker T; Tumas D; Grewal IS; Dixit VM
Nat Immunol; 2001 Jul; 2(7):638-43. PubMed ID: 11429549
[TBL] [Abstract][Full Text] [Related]
17. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members.
Jiang HY; Petrovas C; Sonenshein GE
J Virol; 2002 Jun; 76(11):5737-47. PubMed ID: 11992002
[TBL] [Abstract][Full Text] [Related]
18. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.
Ahmadi T; Flies A; Efebera Y; Sherr DH
Immunology; 2008 May; 124(1):129-40. PubMed ID: 18067555
[TBL] [Abstract][Full Text] [Related]
19. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.
Parsons RF; Yu M; Vivek K; Zekavat G; Rostami SY; Ziaie AS; Luo Y; Koeberlein B; Redfield RR; Ward CD; Migone TS; Cancro MP; Naji A; Noorchashm H
Transplantation; 2012 Apr; 93(7):676-85. PubMed ID: 22262127
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and release of B-lymphocyte stimulator from myeloid cells.
Nardelli B; Belvedere O; Roschke V; Moore PA; Olsen HS; Migone TS; Sosnovtseva S; Carrell JA; Feng P; Giri JG; Hilbert DM
Blood; 2001 Jan; 97(1):198-204. PubMed ID: 11133761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
